Philips announced the launch of its IntraSight Plus interventional guidance platform, a unified system that integrates intravascular ultrasound, physiology, and angiography onto a single screen. The platform received FDA 510(k) clearance and CE marking, confirming its regulatory compliance in the United States and Europe.
IntraSight Plus builds on Philips’ Azurion interventional suite and offers tri‑registration of angiography, physiological assessment, and intravascular imaging. A simulated use study reported up to 47 % savings in system operation time, illustrating the workflow efficiencies the platform delivers.
The first patient case was performed on March 19, 2026 at Cellitinnen‑Krankenhaus St. Vinzenz in Köln, Germany, where a complex three‑vessel STEMI was treated with complete revascularization before discharge.
Philips positions IntraSight Plus as a key component of its AI‑enabled, integrated care solutions, aiming to streamline device placement and result verification and strengthen its competitive stance in the interventional cardiology market.
"As more advanced technology is integrated into the cath lab, the need for connectivity between the imaging tools is more important than ever before. IntraSight Plus was built using feedback from our customers and represents a fundamental shift in interventional cardiology – a future driven by integrated intelligence that lets physicians focus on the decision‑making that only they can do." – Stacy Beske, Business Leader Image Guided Therapy Devices at Philips
Prof. Dr. Jan‑Malte Sinning, who performed the first patient case, added: "Modern PCI is becoming increasingly complex. Intravascular imaging combined with physiology provides the level of detail we need for contemporary PCI. What stands out with IntraSight Plus is that the platform is clearly designed around how we actually work in the cath lab – combining physiology, imaging and decision‑making support in a way that fits naturally into the clinical workflow."
The launch marks a significant milestone for Philips’ diagnostics and treatment segment, expanding its portfolio of AI‑enabled, integrated care solutions and potentially driving new revenue streams as the company leverages its ecosystem of imaging, physiology, and decision‑support technologies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.